Cargando…
Salvage treatment in male patients with germ cell tumours.
The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968255/ https://www.ncbi.nlm.nih.gov/pubmed/8382512 |
_version_ | 1782134700630867968 |
---|---|
author | Josefsen, D. Ous, S. Høie, J. Stenwig, A. E. Fosså, S. D. |
author_facet | Josefsen, D. Ous, S. Høie, J. Stenwig, A. E. Fosså, S. D. |
author_sort | Josefsen, D. |
collection | PubMed |
description | The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > or = 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients). |
format | Text |
id | pubmed-1968255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1993 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19682552009-09-10 Salvage treatment in male patients with germ cell tumours. Josefsen, D. Ous, S. Høie, J. Stenwig, A. E. Fosså, S. D. Br J Cancer Research Article The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > or = 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients). Nature Publishing Group 1993-03 /pmc/articles/PMC1968255/ /pubmed/8382512 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Josefsen, D. Ous, S. Høie, J. Stenwig, A. E. Fosså, S. D. Salvage treatment in male patients with germ cell tumours. |
title | Salvage treatment in male patients with germ cell tumours. |
title_full | Salvage treatment in male patients with germ cell tumours. |
title_fullStr | Salvage treatment in male patients with germ cell tumours. |
title_full_unstemmed | Salvage treatment in male patients with germ cell tumours. |
title_short | Salvage treatment in male patients with germ cell tumours. |
title_sort | salvage treatment in male patients with germ cell tumours. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968255/ https://www.ncbi.nlm.nih.gov/pubmed/8382512 |
work_keys_str_mv | AT josefsend salvagetreatmentinmalepatientswithgermcelltumours AT ouss salvagetreatmentinmalepatientswithgermcelltumours AT høiej salvagetreatmentinmalepatientswithgermcelltumours AT stenwigae salvagetreatmentinmalepatientswithgermcelltumours AT fossasd salvagetreatmentinmalepatientswithgermcelltumours |